ALDEYRA THERAPEUTICS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
ALDEYRA THERAPEUTICS, INC. (ALDX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $1.77 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-06
- ALDEYRA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $1.78, a 71.15% decline year-over-year.
- ALDEYRA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $6.17, a 70.44% increase year-over-year.
- ALDEYRA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $3.62, a 46.45% decline year-over-year.
- ALDEYRA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $6.76, a 61.72% increase year-over-year.
- ALDEYRA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $5.06, a 37.87% increase from fiscal 2024.
- ALDEYRA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $3.67, a 47.27% decline from fiscal 2023.
- ALDEYRA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $6.96, a 71.85% increase from fiscal 2022.
- ALDEYRA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $4.05, a 64.47% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 0 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $1.77 10-Q · filed 2026-08-06 | ||||
| 2026-03-31 | $1.78 10-Q · filed 2026-05-07 | ||||
| 2025-12-31 | $5.06 10-K · filed 2026-02-27 | ||||
| 2025-09-30 | $5.06 10-Q · filed 2025-11-05 | ||||
| 2025-06-30 | $5.05 10-Q · filed 2025-08-07 | ||||
| 2025-03-31 | $6.17 10-Q · filed 2025-05-14 | ||||
| 2024-12-31 | $3.67 10-K · filed 2025-02-28 | ||||
| 2024-09-30 | $3.67 10-Q · filed 2024-11-07 | ||||
| 2024-06-30 | $3.67 10-Q · filed 2024-08-01 | ||||
| 2024-03-31 | $3.62 10-Q · filed 2024-05-02 | ||||
| 2023-12-31 | $6.96 10-K · filed 2024-03-07 | ||||
| 2023-09-30 | $6.96 10-Q · filed 2023-11-03 | ||||
| 2023-06-30 | $6.96 10-Q · filed 2023-08-03 | ||||
| 2023-03-31 | $6.76 10-Q · filed 2023-05-04 | ||||
| 2022-12-31 | $4.05 10-K · filed 2023-03-09 | ||||
| 2022-09-30 | $4.05 10-Q · filed 2022-11-10 | ||||
| 2022-06-30 | $4.04 10-Q · filed 2022-08-05 | ||||
| 2022-03-31 | $4.18 10-Q · filed 2022-05-05 | ||||
| 2021-12-31 | $11.40 10-K · filed 2022-03-17 | ||||
| 2021-09-30 | $11.60 10-Q · filed 2021-10-28 | ||||
| 2021-06-30 | $11.87 10-Q · filed 2021-08-05 | ||||
| 2021-03-31 | $12.24 10-Q · filed 2021-05-06 | ||||
| 2020-12-31 | $3.91 10-K · filed 2021-03-11 | ||||
| 2020-09-30 | $3.91 10-Q · filed 2020-11-05 | ||||
| 2020-06-30 | $3.90 10-Q · filed 2020-08-06 | ||||
| 2020-03-31 | $3.71 10-Q · filed 2020-05-07 | ||||
| 2019-12-31 | $7.71 10-K · filed 2020-03-12 | ||||
| 2019-09-30 | $7.86 10-Q · filed 2019-11-07 | ||||
| 2019-06-30 | $7.92 10-Q · filed 2019-08-09 | ||||
| 2019-03-31 | $8.05 10-Q · filed 2019-05-10 | ||||
| 2018-12-31 | $8.38 10-K · filed 2019-03-08 | ||||
| 2018-09-30 | $8.27 10-Q · filed 2018-11-14 | ||||
| 2018-06-30 | $8.41 10-Q · filed 2018-08-09 | ||||
| 2018-03-31 | $8.50 10-Q · filed 2018-05-15 | ||||
| 2017-12-31 | $5.13 10-K · filed 2018-03-29 | ||||
| 2017-09-30 | $5.12 10-Q · filed 2017-11-09 | ||||
| 2017-06-30 | $5.13 10-Q · filed 2017-08-07 | ||||
| 2017-03-31 | $5.12 10-Q · filed 2017-05-15 | ||||
| 2016-12-31 | $5.43 10-K · filed 2017-03-30 | ||||
| 2016-09-30 | $5.35 10-Q · filed 2016-11-14 | ||||
| 2016-06-30 | $4.96 10-Q · filed 2016-08-10 | ||||
| 2016-03-31 | $4.86 10-Q · filed 2016-05-09 | ||||
| 2015-12-31 | $7.78 10-K · filed 2016-03-30 | ||||
| 2014-12-31 | $6.84 10-K · filed 2016-03-30 | ||||
| 2014-09-30 | $5.19 10-Q · filed 2014-11-12 | ||||
| 2014-06-30 | $8.00 10-Q · filed 2014-08-07 | ||||
| 2013-12-31 | $1.26 10-K · filed 2015-03-23 | ||||
| 2013-06-21 | $3.24 10-K · filed 2015-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |